The combination of TIM3-Apt1 and PDL1-blocking antibody reduced the tumor burden significantly in comparison with the PDL1 blocking monotherapy, which did not display such a remarkable antitumor effect. The gene discussed is HAVCR2; the disease is neoplasm.